Anti-CD20 Antibodies Continue to Improve Outlook in CLL

January 16, 2014
Bonnie Gillis

Oncology & Biotech News, August 2011, Volume 5, Issue 8

The FDA approval of two anti-CD20 antibodies-ofatumumab and, recently, obinotuzumab-has greatly advanced the outlook for managing chronic lymphocytic leukemia.

x